Why is Trump simultaneously murdering people on small boats whose identities we don’t really know (but he insists they’re drug smugglers) while also freeing people we *know* are guilty of drug crimes?
REDHART2 is a simple study - hospitalized for HFrEF --> CPET within 2 weeks of discharge, treatment with anakinra (or placebo, 2:1) for 6 months, CPET repeated at 6, 12, and 24 weeks. Four visits in 6 months all at VCU. Reach out to me or @bvantassell with questions.
Journal publication is a multi-billion industry… and this article estimates that academics donate at least $1.5b annually in labor to support the current enterprise. Write papers, donate reviews, often pay for publication. What a model. researchintegrityjournal.bio… HT @atulbutte
We received feedback on our latest set of faculty surveys but don’t believe it is representative of the faculty because of what we have been told in private meetings. Thanks for participating!
Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure
STAT request: 2021 MeRIT Scholarship Applications due today February 8 at 8pm EST. Receive $3,000 to develop expertise in investigator-initiated research over a 2-year program. Contact lfbuckley@bwh.harvard.edu (@lfbpharmd ) for questions
RHAPSODY trial results just released: Great presentation at AHA2020 by Allan Klein! Full paper on the NEJM. November 16, 2020
DOI: 10.1056/NEJMoa2027892 @AllanLKleinMD1
After sitting in study section last week reviewing proposals for K-series career development awards, thought I'd list my top 5 reasons why such proposals fail. (Not linked to any one submission.)
Junior scientists who might be interested in applying - avoid these pitfalls!!
Remote, algorithm-driven, navigator-administered medication optimization enhanced utilization and dose titration of neurohormonal antagonists versus usual care in HFrEF. This approach may represent a novel strategy to address underutilization of GDMT ja.ma/3c88GPI
COPS trial: in a small RCT, colchicine did not improve a composite of death or CV outcomes at 12 mos post ACS. Small # of events. Adverse non-CV mortality signal (5 vs 0 favoring placebo) 🤷🏽♂️ @UTSWIMchief@UTSWCardfellowahajournals.org/doi/pdf/10.1…
VCUART3 study showed promising benefits of IL-1 blockade with anakinra in STEMI. ahajournals.org/doi/10.1161/…
Looking for other centers in the USA for a phase II trial with a novel IL-1 blocker (contact me antonio.abbate@vcuhealth.org if interested)